-
Mashup Score: 0Program Planner - 2 year(s) ago
Program Planner One fine body�
Source: www.abstractsonline.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0A Rapid, Functional sgRNA Screening Method for Generating Murine RET and NTRK1 Fusion Oncogenes - 2 year(s) ago
CRISPR/Cas9 gene editing technology is an indispensable and powerful tool in the field of cancer biology. To conduct successful CRISPR-based experiments, it is crucial that sgRNAs generate their designed alterations. Here, we describe a simple and efficient sgRNA screening method for validating sgRNAs that generate oncogenic gene rearrangements. We used IL3-independence in Ba/F3 cells as an assay…
Source: bioRxivCategories: Hem/Oncs, Latest HeadlinesTweet-
Non-Rain post, but wanted to give a shout out to my former grad student Laura Schubert for pushing another paper (almost) across the finish line despite rigors of med school. Very cool method to make new murine models using a clever screen with CRISPR. https://t.co/hzMcC4u9BE
-
-
Mashup Score: 0Almost There! - 2 year(s) ago
Your Year In Sport recap is available on the Strava app now.
Source: www.strava.comCategories: Hem/Oncs, Latest HeadlinesTweet-
My 2022 recap from #YearInSport! View yours here: https://t.co/YUSNqMKPpv
-
-
Mashup Score: 0
Nov 04, 2022. NEWARK, Calif., November 4, 2022 (GLOBE NEWSWIRE) — Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead clinical candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced preliminary data in the multicenter, single arm, open-label,…
Source: www.rainthera.comCategories: Hem/Oncs, Latest HeadlinesTweet-
As a physician-scientist, I’m always interested in seeing new data, and last month we released some promising early results from our MANTRA-2 basket study demonstrating the potential of our MDM2 inhibitor to treat a broad range of #cancers. Learn more: https://t.co/gpbyNimDuk https://t.co/xT3SPUaBNE
-
-
Mashup Score: 0About Us - 2 year(s) ago
We are a team of passionate entrepreneurs reinventing drug development
Source: www.rainthera.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Happy Thanksgiving! Spending time with family always reminds me of what we're working towards at @Rain_Thera – developing potential therapies to give patients with #cancer more time to share moments like this with their loved ones. Learn more about Rain: https://t.co/gstMDS6kGw
-
-
Mashup Score: 0What Is Genomic Testing in Cancer? - 3 year(s) ago
A genomic test uses your genes to help your doctor learn more about your cancer and find the best treatment.
Source: WebMDCategories: Hem/Oncs, Latest HeadlinesTweet-
Next Generation Sequencing (NGS) testing provides patients and their clinicians with the most options, both for approved therapies as well as clinical trial options. As a clinician, I ensured that every patient had NGS testing. Learn more here: https://t.co/p5ieyBhvrr
-
-
Mashup Score: 3Next Generation Sequencing - 3 year(s) ago
This JAMA Patient Page describes next generation sequencing, which allows physicians to test many genes of a cancer simultaneously.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Next Generation Sequencing (NGS) testing provides patients and their clinicians with the most options, both for approved therapies as well as clinical trial options. As a clinician, I ensured that every patient had NGS testing. Learn more here: https://t.co/OshE2vXZsY
-
-
Mashup Score: 1Science Programs - 3 year(s) ago
Precision oncology underlies Rain’s developmental philosophy across all its pipeline programs
Source: www.rainthera.comCategories: Hem/Oncs, Latest HeadlinesTweet-
As we continue to progress our #ClinicalTrials assessing @Rain_Thera's investigative drug, I would like to acknowledge our #ClinicalResearch team who work tirelessly behind the scenes to advance targeted therapies for #cancer patients. Learn more here: https://t.co/EfH6WUfhkp
-
-
Mashup Score: 4Breakthrough Therapies: NTRK | IASLC - 3 year(s) ago
In this episode of Lung Cancer Considered, host Dr. Narjust Duma talks with Dr. Robert C. Doebele, Co-Founder and Chief Scientific Officer, Rain Therapeutics ab …
Source: IASLCCategories: Hem/Oncs, Latest HeadlinesTweet-
Really fantastic to have this conversation with @NarjustDumaMD to share my career story (thus far) and the history of TRK inhibitor development. Breakthrough Therapies: NTRK https://t.co/8MaMRjI1vp
-
-
Mashup Score: 0Acquired Resistance Is Oncogene and Drug Agnostic - PubMed - 3 year(s) ago
Recent approvals of TRK inhibitors have demonstrated the success of a tumor agnostic approach to oncogene-targeted therapy across cancers. Collective data from acquired resistance studies suggest that resistance mechanisms, which include both kinase domain mutations and bypass signaling via RTK-RAS- …
Source: PubMedCategories: Latest Headlines, Oncologists1Tweet-
Yes, wrote this editorial a while back to highlight that we see the same bypass pathways coming up as resistance, regardless of drug, driver, or tumor type. https://t.co/WJ8R7Brd8e https://t.co/Y6q9LGRaZY
-
If you’re attending #AACR23, don’t miss out on this compelling presentation exploring the therapeutic potential of MDM2 and MEK inhibition in oncogene-driven NSCLC from our partners @MSKCancerCenter on April 19 at 9 am ET. Learn more here: https://t.co/Z2WyHgjWd5